The Recall Desk
LowFDA (Devices)·Z-0500-2016·Announced 2015-12-30

Ameditech DrugSmart Dip Benzodiazepine Test Recall for Reduced Reactivity

Ameditech is recalling DrugSmart Dip tests because they may show reduced reactivity for Clonazepam and Chlordiazepoxide.

What this means for you

Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.

Our severity reasoning: The recall is classified as FDA Class III, which the rubric defines as unlikely to cause adverse health consequences, typically resulting in a score of 1 or 2.

Plain-English summary

Ameditech Inc is recalling 80 units of the DrugSmart Dip AMP/OPI2/COC/THC/BZO Test, Item No. 30520D. The affected products were distributed nationwide.

The recall was initiated because the tests have shown reduced reactivity for up to two of the nineteen Benzodiazepine (BZO) compounds listed in the product insert. Specifically, the reactivity may be reduced for Clonazepam and Chlordiazepoxide.

The source text does not specify instructions for consumers or healthcare providers on how to handle the recalled units.

The recalled product

Product
DrugSmart Dip AMP/OPI2/COC/THC/BZO Test, Item No. 30520D
Manufacturer
Ameditech Inc
Affected units
80

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (1)

  • 142141 143169

Distribution

Distributed nationwide across the United States.

Part of a larger recall action

This product is one of 59 recalled by Ameditech Inc under a single FDA (Devices) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 59 products in this recall →